Revision as of 10:03, July 1, 2011 (edit)
Wraasch - Sr. Director (Talk | contribs)

← Previous diff
Revision as of 10:04, July 1, 2011 (edit) (undo)
Wraasch - Sr. Director (Talk | contribs)
(Competition)
Next diff →
Line 21: Line 21:
*'''Cinryze:''' Cinryze does not have patent protection, but enjoys exclusivity provided by the FDA in the [[Orphan drug act]]. Once this exclusivity expires near the end of 2015, Cinryze will face generic competition. *'''Cinryze:''' Cinryze does not have patent protection, but enjoys exclusivity provided by the FDA in the [[Orphan drug act]]. Once this exclusivity expires near the end of 2015, Cinryze will face generic competition.
-*'''Vancocin:''' The patents for Vancocin expired in 1996. However, Vancocin is a complex biologic drug, and any generic competition would require significant regulatory hurdles. However, [[Generic Drugs (Biogenerics and Biosimilars)|follow on biologics]] could ct into ViroPharma's sales of Vancocin.+*'''Vancocin:''' The patents for Vancocin expired in 1996. However, Vancocin is a complex biologic drug, and any generic competition would require significant regulatory hurdles. However, [http://www.bio.org/healthcare/followonbkg/Principles.asp|follow on biologics] could cut into ViroPharma's sales of Vancocin.
==References== ==References==

Revision as of 10:04, July 1, 2011

ViroPharma Incorporated (NYSE: VPHM) is a pharmaceutical company that develops and sells two major drugs, Cinryze and Vancocin. In Octover of 2008, ViroPharma acquired Lev Pharmaceuticals, adding an injectable treatment for angiodema to its portfolio, Cinryze. Vancocin is an oral treatment for inflammation of the bowels (colitis). ViroPharma's operators are largely focused on the development and commercialization of these two products.

Business Growth

FY 2010 (ended December 31, 2010[1]

  • Net revenue increased 41% to $439 million.
  • Net income increased 88% to $126 million.

In 2010, revenue growth was driven by Cinryze, a drug used to treat hereditary angiodema, which earned revenue of $177 million for the year, up 82%. Vancocin, a drug used to treat inflammation of the bowels (colitis), brought in sales of $260 million, up 22% on the year.

Pipeline

ViroPharma's pipeline consists of developing new formulations and indications for Cinryze and Vancocin as well as working to market the drugs in other geographies.[2]

  • Cinryze: ViroPharma is partnering with Sanquin to develop a non-injectable version of Cinryze. This version has been moved through phase II trials, and is expected to initiate phase III trials by the end of 2011. In addition, ViroPharma received European approval for Cinryze in June of 2011[3] and is exploring other geographies world-wide.
  • Vancocin: ViroPharma is developing a less toxic version of Vancocin, and is currently initiating phase II trials for the treatment.

Trends and Forces

Competition

  • Cinryze: Cinryze does not have patent protection, but enjoys exclusivity provided by the FDA in the Orphan drug act. Once this exclusivity expires near the end of 2015, Cinryze will face generic competition.
  • Vancocin: The patents for Vancocin expired in 1996. However, Vancocin is a complex biologic drug, and any generic competition would require significant regulatory hurdles. However, on biologics could cut into ViroPharma's sales of Vancocin.

References

  1. ViroPharma Incorporated Reports Q4 2010 Financial Results
  2. VPHM 2011 10K
  3. ViroPharma’s HAE Drug Gets EU Nod
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki